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Abstract 
Background: Atrial fibrillation (AF) is the most commonly observed arrhythmia and is expected 
to increase to over 12 million in the next few decades.  Patients with AF are at high risk of stroke 
due to the use of Coumadin in combination with stroke risk factors such as age >75 years, 
hypertension, diabetes, heart failure, and prior stroke or transient ischemic attack.   Coumadin 
specifically targets the blood clotting cascade by inhibiting the regeneration of vitamin K needed 
for the activation of clotting factors.  A 100 mcg increase in vitamin K intake over at least 4 days 
can reduce patient internationalized national ratio (INR) by 0.2 units. INR values outside of the 
recommended range of 2.0-3.5 increase the risk of intracranial bleeding and stroke.  The 
objective of this study was to assess the understanding of the AF population related to their role 
in reducing the risks associated with Coumadin and the effects of proper understanding on stroke 
risk with a particular emphasis on patient understanding of the interaction between vitamin K 
and Coumadin.   
Methods:  Patients with known AF (n=75) who were receiving treatment from the Utah Heart 
Clinic and were currently taking Coumadin were asked to complete a one-time questionnaire of 
52 questions related to Coumadin use and its’ drug-nutrient interactions. Data collected was 
analyzed to identify any vitamin K and diet knowledge deficits related to nutrition and Coumadin 
use.   
Results:  Sixty-eight of the patients had at least one risk factor for stroke with hypertension, the 
most common stroke risk factor (58.7% of the population). Age > 75 years was the second most 
common, followed by heart failure.  Only 63.9% of the patient population had some 
understanding of diet/vitamin K and Coumadin use.   
Conclusion: This study demonstrates a lack of patient knowledge regarding the interaction of 
Coumadin and nutrition/vitamin K in patients with additional stroke risk factors.   
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Introduction 
Atrial Fibrillation and Stroke 
Atrial fibrillation (AF) is the most commonly observed arrhythmia in clinical practice. 
The number of people affected by AF is expected to increase from 5.6 to over 12 million in the 
next few decades (1,2).  Both the Framingham study and a cohort from Olmsted County, 
Minnesota have shown age-adjusted increases in the prevalence and incidence of atrial 
fibrillation from the 1960’s to 1989 (3-4).  While age is a key risk factor for AF, other population 
demographics may also contribute to the increased prevalence of AF. The epidemiologic changes 
of AF are a global phenomena. The incidence and prevalence of AF in the Netherlands are 
similar to those in the US. AF admissions are also on the rise in China (5-6).   
In patients with AF, systemic embolization can result from stasis in the left atrium and 
appendage, leading to stroke, significant morbidity, and/or mortality.  Although absolute stroke 
risk varies among AF patients, stroke risk can be stratified based upon clinical and 
echocardiographic variables. Stroke risk factors, identified over the course of five AF prevention 
trials, include age >75 years, hypertension, diabetes, heart failure, and prior stroke or transient 
ischemic attack.  There is a significant benefit obtained from the use of the anticoagulant 
medication Coumadin, as compared to aspirin, for the prevention of stroke in AF patients, 
particularly those at highest risk (i.e., those with more than one baseline risk factor) (7-11). 
Risks of Coumadin Use 
Although Coumadin is effective in reducing stroke, it carries with it the major concern of 
intracranial bleeding (12).  The adjusted odds of developing intracranial bleeding (relative to an 
internationalized national ratio (INR) of 2.0 to 3.0) were 4.6 and 8.8 for INRs in the range of 3.5 
to 3.9 and ≥ 4.0, respectively (12). Elderly patients and those with prior cerebrovascular disease 
represent some of the highest risk populations for stroke. However, these groups are also at 
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highest risk for intracranial bleeding with Coumadin anticoagulation. Similarly, risk of 
thromboembolism increases significantly when the INR is subtherapeutic, less than 2.0 (13).   
Due to the risks of over- and under-coagulation, chronic use of Coumadin requires frequent 
INR/protime monitoring. 
Coumadin anticoagulant Control and Education 
To attenuate the risk of intracranial bleeding and stroke, good anticoagulation control 
becomes essential in the long-term management of patients with AF.  However, maintenance 
doses of Coumadin vary significantly, ranging from less than 2 mg/day to ≥ 10 mg/day. The 
variability stems from many factors including: nutritional status, hepatic function, intestinal 
absorption, compliance, drug interactions, and genetic polymorphisms (14-16). Of these factors, 
understanding of drug interactions, nutrition, and compliance are those that can be positively 
influenced through intervention and education, improving patient outcomes.   
Coumadin and Drug Interactions 
Many drugs interact with the metabolism of Coumadin. The number increases almost 
daily as new drugs enter the patient market. These drugs can lead to overanticoagulation, 
underanticoagulation, or increased bleeding risk by INR independent changes, such as altered 
platelet function or gastrointestinal bleeding. Interactions with medications in patients taking 
Coumadin are a widespread problem in clinical practice. For example, in one study, nearly one-
third of patients taking Coumadin had also been prescribed a medication known to adversely 
interact with Coumadin (17).  Consequently, patients must be instructed not to take any new 
medications, including herbal products/supplements or over-the-counter medications, without the 
knowledge of their attending physicians. Although education communicating these ideas is 
widely available and frequently used for patients with cardiac disorders (e.g., Long QT 
syndrome), it is not frequently used for patients taking Coumadin. 
Vitamin K and its Role 
Related to nutrition, vitamin K intake must be closely monitored, as it is a key nutrient 
that interacts with anticoagulation therapy.  Vitamin K plays a key role in the blood clotting 
cascade.  Vitamin K’s principal action in blood clotting is to enable the generation of the active 
cofactor needed for carboxylation of glutamic acid, which interacts directly with clotting factors 
II, VII, IX, X, prothrombin, and specific clotting proteins (see Figure 1).  Synthesis of glutamic 
acid allows for the binding of these factors and proteins to calcium, which is required for 
incorporation into the clotting cascade (18-20).   
Figure 1: Clotting Cascade - Vitamin K affects clotting factors II, VII, IX, and X (21)  
King, Michael W.  Blood Coagulation: The Clotting Cascades. Indiana University School of 
Medicine Medical Biochemistry.  November 19, 2008. http://themedicalbiochemistrypage.org 
(21) 
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Interaction Between Vitamin K and Coumadin 
Coumadin specifically targets the blood clotting cascade by inhibiting the regeneration of 
vitamin K from vitamin K epoxide.  Thus, the medication blocks the generation of the cofactor 
required in the carboxylation of glutamic acid and the ability of the clotting factors to bind to 
calcium and participate in the clotting cascade (18-20).    Due to decreased regeneration of 
vitamin K, the formation of vitamin K dependent clotting factors is much more susceptible to 
dietary intake (19).  Consequently, intake of vitamin K, either through foods or supplementation, 
can alter the effect of Coumadin. 
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Figure 2: Coumadin interaction with Vitamin K (22) 
tute: Micronutrient Research for 
Optimum Health. May 2004. http://lpi.oregonstate.edu/infocenter/vitamins/vitaminK/kcycle.html
Higdon, Jane.  The Vitamin K Cycle. Linus Pauling Insti
 
min K Sources and RDA 
ietary vitamin K are dark green vegetables such as broccoli, 
e of 
(22) 
 
Vita
 The primary sources of d
spinach, collard greens, romaine lettuce, and vegetables oils.  From diet alone, the mean intak
vitamin K is between 74 and 117 mcg/day in adults, which meets the current adequate intake 
(AI) requirement of 90 mcg/d for adult women and 120 mcg/day for adult men (23-24).  For 
8 
 
e 
h 
those taking Coumadin, the National Institute of Health recommends keeping vitamin K intak
constant with no more than one serving of foods high in vitamin K and three servings of foods 
moderately high in vitamin K per day (23).  Research regarding vitamin K and Coumadin has 
reported intakes as low as 29 to 40 mcg/day (19-24).  Vitamin K intake is highly correlated wit
serum vitamin K, and some studies have noted serum levels less than 1.5 mcg/L compared to a 
normal value, which is considered to be greater than 4.5 mcg/L, in patients taking Coumadin 
with unstable anticoagulation control (23). 
Table 1: Sources of Vitamin K  
Phylloquinone (Vitamin K) mcg/100g 
< 10 10-50 > 100 > 200 
Milk Broccoli Asparagus Cabbage 
Butter Celery Lettuce Kale 
Eggs  Green benas prouts rd Brussels s Swiss cha
Cheese Avocado Mustard Greens Turnip 
Meats Kiwi Soybean oil Watercress greens 
Fish Pumpkin (canned) Canola oil Collards 
Corn  Peas  Spinach 
Cauliflower ns Peanut Butter  Salad gree
Grains Lentils   
Fruits (most) Kidney Beans   
Brewed tea Pinto Beans   
Tomatoes Soybeans   
 Coffee (brewed)   
 Olive oil   
Source: Groper SS, Smit vance  Nutrition and Human Metabolism. 4th ed. 
adsworth 2005 (25). 
h JL, Groff JL.  Ad d
W
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able 2:  Vitamin K Adult RDA Values 
 
T
Vitamin K Adequate Intake (AI) 
Age/Gender Vitamin K AI in mcg/d 
Male > 19 years 120 
Female > 19 years 90 
Source: Groper SS, Smith JL, Groff JL.  Advanced Nutrition and Huma tabolism. 4th ed. 
5). 
he Effect of Vitamin K Intake on INR 
een vitamin K and Coumadin, it is important to 
 on 
se 
e 
once 
pared to patients with stable INR values have 
consist ied 
ly 
n Me
Wadsworth 2005 (2
 
T
 When assessing the interaction betw
monitor INR to assess the effect of dietary intake on the effectiveness of the Coumadin dose
blood clotting.  The ideal INR range for AF patients taking Coumadin is 2.0-3.0 (23).  Weekly 
changes of 714 mcg of dietary vitamin K intake have been found to significantly affect weekly 
INR values by one unit, equivalent to a weekly change in a Coumadin dose of 14.5 mg (18).  
Vitamin K intake of 150 mcg in women and 200 mcg in men is enough to significantly decrea
INR.  For every 100 mcg increase in vitamin K intake over at least 4 days, INR has been found 
to reduce by 0.2 units (18,23-24).  Anticoagulant therapy with Coumadin is targeted at 
maintaining INR values between 2.0-3.0 to balance the risk between stroke and excessiv
bleeding.  Intakes as low as 250 mcg can contribute to unstable anticoagulant therapy, and 
vitamin K intake exceeds 500 mcg, it has been shown to reverse anticoagulation therapy (18).   
Vitamin K and Unstable Anticoagulation 
Patients with unstable coagulation com
ently lower intakes of vitamin K.  The impact of changes in vitamin K intake is amplif
in patients with compromised vitamin k status and low serum values.  In addition, it has been 
found that a patient’s INR decreases with addition of a multivitamin supplement containing on
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ry 
25-50 mcg of vitamin K were found to significantly lower dietary intake and serum levels of 
vitamin K (19,20).  Although patients are cautioned about leafy vegetables that can contain ve
high levels of vitamin K (one-half cup of frozen spinach contains >500 micrograms of vitamin 
K), other high vitamin K products are less well-known, such as herbal supplements and 
multivitamins (26).  
Vitamin K and Coumadin Dosing 
 mcg of vitamin K per week requires on average a 
Couma  500-
n 
ther 
ts 
le adverse effects, many of which patients may 
 
ontact 
.  As 
understand the importance of frequent testing.   
Consumption of less than 500
din dose of 35 mg/wk compared to 38 mg/wk Coumadin for vitamin K intakes of
1000 mcg/wk and 37 mg/wk Coumadin for intakes greater 1,000 mcg/wk of vitamin K (18).  A
average Coumadin dose increases from 3.5 mg/day to 5.7 mg/day with vitamin K intakes below 
250 mcg/d and above 250 mcg/d, respectively (24).   Participants, whose vitamin K intake 
remained constant, manifested little or no change in Coumadin dosing after correcting for o
drug and supplement interactions. This finding supports the recommendation to consume a 
consistent amount of vitamin K (18,23-24).   
Patient Knowledge of Coumadin Side Effec
 Coumadin is a medication that has multip
be unaware of.  In addition to using frequent INR testing, the main overt sign of inappropriate 
anticoagulation therapy is excessive bleeding or bruising.  A pre-test administered by Mazor et
al. (27) showed that 5% of participants were not aware that it was important to contact the 
anticoagulation clinic if they had a cut that would not stop bleeding, 13% did not know to c
the clinic if they noticed unexplained bruising or blood in their urine or stools, and 35% of 
participants did not know that excessive Coumadin could cause a gastrointestinal bleed (27)
INR can measure inappropriate responses to anticoagulation therapy, it is imperative that patients 
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on was a problem and 12% reported being able 
to tell i
validated benefits. In 
 patients, nonadherence to Coumadin was estimated at 21%; the patients 
sample
h 
 
 range of 2.0-3.5 increase the risk of intracranial 
1).  The relationship between vitamin K intake and changes in INR leading 
to over
In assessing patient attitudes towards INR testing, 13% of the pre-test respondents did not 
believe that missing a lab appointment on occasi
f their Coumadin was at the right level by how they physically felt (27).  Finally, 83% of 
participants were aware that too little Coumadin could cause a stroke, but only 21% were aware 
that too much Coumadin could cause a stroke (27).  Patients must be aware of the overt signs of 
inadequate coagulation and the importance of INR testing to appropriately monitor 
anticoagulation therapy and reduce risk of excessive bleeding and stroke.   
Patient Compliance 
Compliance to medications of any type is essential to receive study-
a prior study of elderly
d missed pills more often rather than took too many (28). One important additional 
finding was that patients often perceived that they were more adherent than they actually were 
throughout the study. It is likely that patients not enrolled in a study will actually have muc
higher rates of nonadherence and will be at risk for either bleeding or thromboembolism as a 
result.  Even if vitamin K education and knowledge in relation to Coumadin use is adequate it
may not translate into appropriate INR values. 
Research Objective 
INR values outside of the recommended
bleeding and stroke (1
- and under-anticoagulation has been established (19-20,23-24).  Although medical 
knowledge is not yet advanced enough to remediate many of the primary causes of variability, 
intervention and education focusing on proper nutrition and vitamin K intake may improve 
patient outcomes (14-16).  
12 
 
nd 
d intracranial bleeding risk.  The objective of this study was to assess 
the und  
 Utah) in 
y (Logan, Utah).  Patients with known AF (n=75) who 
were re din were 
n.  
any 
e deficits related to nutrition and Coumadin use. The data was stratified by stroke risk.  
Resul
ssess differences between male and female. The patients were categorized according 
to strok troke 
To date, few, if any, studies have measured patient understanding of Coumadin use a
its implications in stroke an
erstanding of the AF population related to their role in reducing the risks associated with
Coumadin and the effects of proper understanding on stroke risk with a particular emphasis on 
patient understanding of the interaction between vitamin K and Coumadin. 
Research Design and Methods 
This study was conducted at Intermountain Medical Center (Murray,
collaboration with Utah State Universit
ceiving treatment from the Utah Heart Clinic and were currently taking Couma
asked to complete a one-time questionnaire of 52 questions related to Coumadin use and its 
interactions. Participation was voluntary and no identifying information was obtained. The 
questionnaire was completed under the supervision of a registered dietitian or student dietitia
The study was approved by the Utah State University Institutional Review Board (protocol 
#2187).  
The data collected was analyzed to identify any vitamin K, vitamin supplement, and 
knowledg
ts  
The mean age of the patient population was 69.2 (n=75). The data was stratified by 
gender to a
e risk, based on the CHADS2 Score. The CHADS2 score is used to estimate risk of s
in AF patients (7-11).  
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 Sixty-eight of the patients had at least one risk factor for stroke (see Table 1). The seven 
remaining patients with no stroke risk factors were taking Coumadin because they had recently 
undergone a cardiac ablation.  
 Hypertension was the most common stroke risk factor (58.7% of the population). Age > 
75 years was the second most common, followed by heart failure. 
Table 1.  Stroke Risk Characteristics 
_____________________________________________________________________________ 
 
Item        M+F      M     F 
 n(%)      n(%)    n(%) 
_____________________________________________________________________________ 
n         75       47     28 
Age        69.2      66.7    72.3 
 
Stroke Risk 
 
1. Hypertension     44(58.7)     28(59.6)   16(57.1)  
2. Heart failure     25(33.3)     14(29.8)   11(39.3) 
3. Age > 75      26(34.7)     12(25.5)   14(50.0) 
4. Diabetes      12(16.0)     7(14.9)    5(17.9) 
5. TIA        19(25.3)     11(23.4)   8(28.6) 
7. TIA on Coumadin    6(8.0)      3(6.6)    3(10.7) 
_____________________________________________________________________________ 
 To assess general knowledge concerning Coumadin use, the data was categorized by 
response to certain questions in the questionnaire. Questions pertaining to diet in regards to 
Coumadin use were assessed.  The following questions were used to assess knowledge: “Do you 
think getting enough vitamin K is important?”; “What do you think Vitamin K does for us?”;  
“Do you know how to interpret a supplement facts label?”;  “Can changing your diet change 
your Coumadin dose?”;  “Are you aware that you get vitamin K from the foods you eat?”; “Do 
you know how to interpret a nutrition facts label?”;  and “Is it important to watch how much 
vitamin K you get each day when you are on Coumadin?”   If the patient answered yes to one of 
the aforementioned questions, it was deemed that the patient had some knowledge related to 
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Coumadin use. Table 2 represents the percent of the patient population who had some 
understanding of diet and Coumadin use. 
Table 2.  Coumadin Knowledge 
________________________________________________________________ 
 
Item        M+F    M     F 
________________________________________________________________ 
 
Dietary influence (%)    63.9    65.1    61.8 
________________________________________________________________ 
 
Discussion 
 
 Seventy-five patients participated in this study. Of these, 68 had at least one stroke risk 
factor. Because only seven participants did not have at least one stroke risk, data was not 
analyzed by stroke risk versus non-stroke risk as originally intended. In the future, data will be 
stratified based on the number of stroke risks based on the CHADS2 score. 
 This study found that 63.9% of the population had some knowledge related to diet and 
Coumadin use. Because the data was categorized by response to certain questions, the results do 
not identify any differences in knowledge regarding the differences in questions asked. In the 
future, the questions will be weighted by importance to assess the degree of knowledge of diet 
and Coumadin use.  
Changes in INR are observed with short-term vitamin K intake; however, INR values and 
Coumadin dosing are not affected over an extended period of time if vitamin K intake returns to 
levels normally consumed by participants (23-24).  Schurgers et al. (23) found that meals with a 
large amount of vitamin K rich foods significantly decreased INR by 0.3-0.6 units.  However this 
effect was not maintained past three to seven days (23).   Khan et al. (24) demonstrated a change 
of 0.2 units in INR with 100 mcg/d increases in vitamin K over a 4 and 7-day period.  However, 
when INR levels were measured over 28 days following changes in vitamin K intake there was 
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no significant change in INR compared to baseline (24).  Once Coumadin dosing has been 
established and INR levels stabilize, most patients have their INR tested monthly.  Short-term 
changes in vitamin K intake that affect INR levels may not be noticed in monthly lab values due 
to the stabilization of INR over time.  This could be a concern with patients who are not aware of 
the interaction of vitamin K and have a great variability in dietary vitamin K intake.   
 Patients taking Coumadin are instructed to maintain a consistent intake of vitamin K (23).  
This can easily be misconstrued to mean that foods containing vitamin K should be avoided.  In 
addition, if patients are unaware of what foods contain vitamin K, it impacts their ability to 
maintain consistency in vitamin K intake and may lead to avoidance of foods, which contain 
little or no vitamin K (20).  Misinterpretation of vitamin K recommendations may be the cause of 
low dietary intake and serum vitamin K levels found in patients with unstable control (20).  In 
patients with low vitamin K intake and serum levels, use of a multivitamin containing 25 mcg of 
vitamin K has been found to decrease INR by a median of 0.51. For those patients with normal 
serum vitamin K levels who consume the RDA of vitamin K, use of a multivitamin containing 
25 mcg of vitamin K has been found to have no significant change in INR (23). 
 Chronic low dosing of vitamin K may attenuate INR changes in response to small 
variations in vitamin K intake in those patients with low serum values.  Sorano et al. (29) 
demonstrated an improvement of anticoagulation therapy when patients consume at least 20-40 
mcg/day of vitamin K.  The effectiveness of chronic supplementation of vitamin K needs to be 
investigated further to determine if this is feasible and safe.  Furthermore, changes in patient 
education regarding Coumadin may help improve patients understanding of appropriate intake of 
vitamin K and in what products it can be found. 
 Couris et al. (30) developed a brief, self-assessment instrument (K-Card) to determine daily 
variations in dietary vitamin K intake that could be validated and used in the assessment of patients 
16 
 
receiving oral Coumadin anticoagulant therapy.  The K-card included foods that previous studies have 
shown provide 5 mg vitamin K per serving, foods with lower vitamin K contents that are consumed in 
larger quantities, and common supplements and herbal products.  The items listed were color coded into 
categories such as vegetables, meat/poultry/fish, mixed dishes, fats/oils/salad dressings, snacks, desserts, 
beverages, and dietary supplements (30).  The mean dietary vitamin K intake estimated using the K-Cards 
was 138.8 +/- 15.7 mg compared to diet record averages of 136.0 +/- 15.8 (30).  Self-assessment 
measures such as the K-Card can accurately assess vitamin K status and may be helpful in increasing 
patient understanding of what foods contain vitamin K.   
 This study showed that over 30% of patients were unaware of the effects of nutrition and 
vitamin K on Coumadin therapy and stroke risk.  While 63.9% of patients had some knowledge 
of vitamin K and its interaction with Coumadin, they may have only answered one question 
regarding nutrition and vitamin K correctly.  The percent of patients who have some knowledge 
regarding nutrition and Coumadin may be overstated, as it does not account for the level of 
knowledge the patient had about this relationship or the level of awareness the patient had 
pertaining to what foods and products contained vitamin K.  In short, many patients are still 
lacking the necessary education regarding Coumadin to maintain adequate INR values and 
minimize the risk of stroke and intracranial bleeding. 
 In a randomized clinical trial conducted by Khan et al. (31), 125 patients over the age of 
65 were divided into three groups: patients who received usual clinical care, patients who 
received additional education regarding Coumadin, and patients who received additional 
Coumadin education in combination with education on how to self-monitor INR.  Coumadin 
education was done in a two-hour session given to patients in groups of 2-3 that covered 
information regarding atrial fibrillation, clinical benefits and risk of Coumadin use, and factors 
that affect INR with emphasis on drug interactions and diet (31).  The INR standard deviation 
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decreased by 0.24 in the combination group, 0.26 in the Coumadin education group, and only 
0.16 in the control group meaning that those who received additional Coumadin education 
beyond usual care had a decreased variability in INR (31).  
Although personalized patient education is effective in increasing patient knowledge, it is 
costly and time consuming for healthcare employees.  Mazor et al. (27) compared the 
effectiveness of videos depicting dialogue between a physician and patient regarding Coumadin 
use and its interactions to a control group who received standard care.  Coumadin-related 
knowledge and belief in the importance of lab testing improved between pre and post-test for 
those patients who viewed the educational video, either with statistical evidence, narrative 
evidence, or a combination of both, compared to the control group who received usual care and 
not the educational video (27).  Additional attention toward administration of appropriate 
education can lead to increased patient knowledge. 
 Stone et al. (32) compared the use of personalized patient education with the use of 
educational videotapes.  Both groups scored significantly higher on post education 
questionnaires designed to assess knowledge.  In addition, this study found no difference in 
knowledge improvement between patients who received Coumadin education through 
personalized teaching or videotape (32).  A follow-up questionnaire showed that patients in each 
group rated the effectiveness and importance of the education equally (32).   
   One-on-one teaching by physicians and nurses is time consuming. In the current era of 
both physician and nursing shortages, one-on-one teaching is not feasible for diseases that are 
highly prevalent in the community, such as AF. An alternative is group teaching through 
audiovisual presentations (videotapes, DVDs, or internet-based). Audiovisual presentations have 
been shown to be effective tools if the presentations are appropriate for the audience, brief and 
focused, and deliver the necessary information (33-35).  Patients can view these presentations in 
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their homes as frequently as needed.  One addition concern to using these educational methods to 
increase knowledge is how to ensure knowledge is translated to action and improved patient 
results. 
Conclusion 
 This study demonstrates a lack of patient knowledge regarding the interaction of 
Coumadin and vitamin K in patients with additional stroke risk factors.  Inadequate education 
regarding vitamin K and its interaction with Coumadin can lead to an increased risk of stroke and 
intracranial bleeding (12,13,18).  Education of the drug-nutrient interaction of Coumadin can 
reduce patient risk when coupled with compliance and can be effectively administered through 
audiovisual mediums.  Further research is warranted to quantify the effect of lack of patient 
knowledge on morbidity and mortality and appropriate educational interventions (31).  
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Age ________ 
 
Please circle: 
 
Gender     
Male        
Female      
           
Education Level 
Less than the 8th Grade 
8-12th Grade  
High School Graduate 
College Graduate 
Advanced Degree 
 
Stroke Risk Factors 
1.  High blood pressure:  Yes/No 
2.  Heart failure:  Yes/No 
3.  Age greater than 75 years:  Yes/No 
4.  Diabetes:  Yes/No 
5.  Prior stroke or mini-stroke (TIA):  Yes/No 
7.  Prior stroke or mini-stroke when on Coumadin:  Yes/No 
If you had a stroke on Coumadin, was your blood level: 
a. Too low   
b. Normal 
c. Too high 
d. Not sure 
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Other Cardiac Problems 
1.  Have you had a prior heart attack:  Yes/No 
2.  Have you had a stent or bypass surgery:  Yes/No 
3.  Do you have any problems with your heart valves:  Yes/No 
 If yes, was the problem: 
 a. Narrow 
 b. Leaky 
 c. Not sure 
4.  Have you had surgery for your heart valves:  Yes/No 
Please answer the following questions: 
1.  Have you ever experienced bleeding in your urine or stools?  Yes/No 
2.  Have you ever received a blood transfusion because of bleeding?  Yes/No 
3.  Have you fallen in the past year?  Yes/No 
4.  If you have fallen in the past year, how many times? _____ 
5. How long have you been on Coumadin? 
a. Less than 1 year 
b. 1 year – 5 years 
c. 5 years – 10 years 
d. Greater than 10 years 
e. Not sure 
6. Do you take your Coumadin as prescribed by your doctor? Yes/No 
7. Do you ever skip your Coumadin dose? Yes/No 
8. Do you ever double up your Coumadin dose? Yes/No 
9.  Do you ever not refill your Coumadin because of cost?  Yes/No 
10. What is the most common reason why you may not take your Coumadin dose? 
 a. Cost 
 b. Forgetting 
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 c. Mixing up medications 
 d. Lack of desire 
 e. Illness 
 f. None of the above 
11.  Have you gained weight after starting Coumadin?  Yes/No 
12.  If yes, approximately how much weight have you gained? _____ 
13.  If yes, why do you think you gained the weight? (Circle all that apply) 
 a.  Changed diet and avoided vegetables 
 b.  Exercised less 
 c.  Ate more at each meal 
 d.  Craved new foods that were less healthy 
14. Have you lost weight after starting Coumadin? Yes/No 
15. If yes, approximately how much weight have you lost? _____ 
16. If yes, why do you think you lost the weight? (Circle all that apply) 
 a. Changed diet and avoided many foods 
 b. Illness 
 c. Ate less at each meal 
 d. Stopped drinking alcohol 
17. What is considered a normal INR (blood Coumadin level)? 
 a. Less than 1 
 b. 2-3 
 c. 4-5 
 d. Greater than 5 
 e. Not sure 
18. Do you know what your current INR (blood Coumadin level) is? Yes/No 
19. Approximately how often do you get your INR (blood Coumadin level) checked? 
 a. Once a week 
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 b. Twice a month 
 c. Once a month 
 d. Twice a year 
 e. Once a year 
 d. Never 
 f. Not sure 
20.  Do you ever not get your INR (blood Coumadin level) checked because of cost?  Yes/No 
21. Are you aware that your other medications can interact with Coumadin?  Yes/No 
22. Do you ask your pharmacist before starting a new medication if it interacts with Coumadin?  Yes/No 
23. Do you ever take over-the-counter pain medications? Yes/No 
24. If yes, which ones? (Circle all that apply) 
Excedrin®  Tylenol® (Acetaminophen)  Aleve® (Naproxen) 
Advil® (Ibuprofen)  Motrin® (Ibuprofen)   Aspirin 
25. Do you ask your doctor before using over-the-counter pain medications? Yes/No 
26. Do you ever take over-the-counter stomach remedies? Yes/No 
27. If yes, which ones? (Circle all that apply) 
Tagamet HB® (Cimetidine) Pepto Bismol® (Bismuth Subsalicyclate) 
Laxatives   Stool Softeners 
Alka-Seltzer® 
28. Do you ask your doctor before using over-the-counter stomach remedies? Yes/No 
29. Do you take vitamin supplements? Yes/No 
30. If yes, which ones (Circle all that apply) 
  Multivitamin (Dose:     ) 
 Vitamin A  (Dose:     ) 
 Vitamin E  (Dose:     ) 
 Vitamin D  (Dose:     ) 
 Vitamin C (Dose:     ) 
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31. Are you aware that vitamin supplements can interact with Coumadin? Yes/No 
32. Do you ask your doctor before using a vitamin supplement if it interacts with Coumadin?  Yes/No 
33. Do you think getting enough Vitamin K is important? 
 a. Yes 
 b. No 
 c. Not sure 
34.  What do you think Vitamin K does for us? (Circle all that apply) 
 a.  Improves eye sight 
 b.  Strengthens bones 
 c.  Improves the texture and softness of skin 
 d.  Helps to form clots 
 e.  It is an anti-oxidant to help the body  
35. Do you take any herbal or natural medications or supplements?  Yes/No 
36.  If yes, which ones? (Circle all that apply) 
 Garlic   Ginger   Glucosamine 
 Ginko Biloba  CoEnzyme Q10 Green Tea 
 St. John’s Wort Flaxseed  Melatonin 
 Papaya Extract Ginseng  Soy Protein Products  
 Fish oil supplements that contain EPA or DHA  
37. Are you aware that natural medications or supplements can interact with Coumadin? Yes/No 
38. Do you ask your doctor before using a natural medication or supplement if it interacts with 
Coumadin?  Yes/No 
39. Do you know how to interpret a supplement facts label on natural medications or supplements? 
Yes/No 
40. How often do you drink alcoholic beverages? 
 a. Every day 
 b. 4-6 days a week 
 c. 2-3 days a week 
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 d. Once a week 
 e. 2-3 times a month 
 d. Once a month 
 e. Less than once a month 
 f. Never 
41. How often do use tobacco products? 
 a. Every day 
 b. 4-6 days a week 
 c. 2-3 days a week 
 d. Once a week 
 e. 2-3 times a month 
 d. Once a month 
 e. Less than once a month 
 f. Never 
42. Can changing your diet change your Coumadin dose? 
 a. Yes 
 b. No 
 c. Not sure 
43. How often do drink grapefruit juice or eat grapefruit? 
 a. Every day 
 b. 4-6 days a week 
 c. 2-3 days a week 
 d. Once a week 
 e. 2-3 times a month 
 d. Once a month 
 e. Less than once a month 
 f. Never 
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44. Are you aware that grapefruit and grapefruit juice interact with Coumadin? 
 a. Yes 
 b. No 
 c. Not sure 
45. Are you aware that you get Vitamin K from the foods you eat? 
 a. Yes 
 b. No 
 c. Not sure 
46. How much Vitamin K do the following foods contain? Please circle the amount: 
Cooked broccoli 
(1 cup) 
0-9 mcg 10-29 mcg 30-89 mcg 99-1200 mcg 
Vegetable Oil (1 
Tbsp) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Canned tuna in oil 
(3 oz) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Iceberg lettuce (1 
cup) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Cooked spinach (1 
cup) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Coleslaw (3/4 cup) 0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Red grapes (1 cup) 0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Green leaf lettuce 
(1 cup) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Walnuts (14 
halves) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Grapefruit juice (1 
cup) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Red wine (3.5 fl 
oz) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Olive Oil (1 tbsp) 0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
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Cooked asparagus 
(4 spears) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Raw celery (1 
stalk) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Vanilla ice cream 
(1/2 cup) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Avocado (3 oz) 0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
75% lean ground 
beef (3 oz) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Roasted chicken (1 
drumstick) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Raw pineapple (1 
cup) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Cooked salmon 
(1/2 fillet) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Swiss cheese (1 
oz) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
2% milk (1 cup) 0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Hard-boiled egg (1 
large) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
Chunky peanut 
butter (1 Tbsp) 
0-9 mcg 10-24 mcg 25-99 mcg 100-499 mcg 
 
47. Do you know how to interpret a nutrition facts label on food products? Yes/No 
48. How many meals do you eat each day? 
 a. One 
 b. Two 
 c. Three 
 d. Four 
 e. Five 
 f. Less than one 
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 g. More than 5 
49. How many meals do you eat each day with Vitamin K? 
 a. One 
 b. Two 
 c. Three 
 d. Four 
 e. Five 
 f. Less than one 
 g. More than 5 
 h. Not sure 
50. Is it important to watch how much Vitamin K you get each day when you are on Coumadin? 
 a. Yes 
 b. No 
 c. Not sure 
51.  Do you believe that taking Coumadin negatively influences your quality of life?  Yes/No 
52.  If yes, why do you think Coumadin negatively influences your quality of life? (Circle all that apply) 
a.  Frequent blood draws 
b.  Don’t get to eat your favorite foods 
c.  Diet is too restrictive 
d.  No longer drink alcohol or only occasionally 
e.   Worry about bleeding  
f.   Feel unwell or experience side effects on the medication 
 
 
 
 
